Cytotoxic T-lymphocytes (CTLs) are the effector cells of the adaptive immune system that exclusively recognize MHC-I presented antigens, thus having a central role in the recognition and clearance of malignant cells.^[@bib1],\ [@bib2]^ A complex interplay of stimulatory and inhibitory receptor-ligand interactions, as well as inflammatory cytokines orchestrate the activation of CD8^+^ T cells and their differentiation into CTLs.^[@bib3]^

To control the magnitude of T-cell responses, the inhibitory surface receptor CTLA-4 has been identified as a primary attenuator of T cells.^[@bib4],\ [@bib5]^ Furthermore, CTLA-4 is overexpressed in exhausted CTLs during chronic diseases alongside other inhibitory receptors such as PD-1 (ref. [@bib6]). Its blockade during immune-checkpoint therapy promisingly restores anti-tumor immunity in mice and men.^[@bib7],\ [@bib8],\ [@bib9]^ CTLA-4 has already been shown to be involved in the regulation of CD8^+^ T cells;^[@bib10],\ [@bib11]^ however, the mechanisms by which CTLA-4 controls CTL responses still remain incompletely understood. Because of the temporary delayed increase of receptor expression, CTLA-4 strongly impacts on highly activated cells with already established transcription profiles.^[@bib12]^ We therefore hypothesize that CTLA-4 could exploit posttranscriptional or -translational mechanisms to modulate CD8^+^ T-cell differentiation.

In this study we characterized the phosphoproteome response that resulted from CTLA-4 engagement in activated CD8^+^ T cells by using iTRAQ quantitative mass spectrometry. The analysis identified previously unknown targets and mechanisms how CTLA-4 affects CD8^+^ T-cell differentiation. We confirmed that CTLA-4-mediated mechanisms abrogated the phosphorylation of the AP-1 family transcription factor Fos-related antigen 2 (Fra-2) and led to a nuclear re-localization of the central transcription factor FoxO1, which caused a strong induction of the translational inhibitor programmed cell death-4 (PDCD4). Strikingly, PDCD4-deficient CTLs showed enhanced production of the otherwise repressed effector molecule IFN-*γ* and loss of PDCD4 ultimately resulted in superior control of tumor growth *in vivo*. This novel pathway delineates how CTLA-4 is able to regulate CD8^+^ T-cell differentiation and the identified mechanisms further provide new strategies to improve anti-tumor immune responses.

Results
=======

CTLA-4 modulates central CD8^+^ T-cell processes
------------------------------------------------

To identify novel proteins and signaling mechanisms exclusively targeted by CTLA-4 in CD8^+^ T cells, we performed a comparative mass spectrometry analysis of phosphorylated proteins from cells that were differentiated *in vitro* with or without CTLA-4 engagement concomitant with *α* CD3 and *α* CD28 activation ([Supplementary Figure S1a](#sup1){ref-type="supplementary-material"} upper).^[@bib4]^ To control the effectiveness of CTLA-4-mediated signals we monitored CD8^+^ T cells by flow cytometry. The cells showed equal activation on day 1 as controlled by proliferation, CD62L downregulation, CD44 and T-bet expression; however, CD8^+^ T cells that received a CTLA-4 stimulus had 55% less IFN-*γ* producers on day 2 and less than one-fifth on day 3 ([Supplementary Figures S1b-d](#sup1){ref-type="supplementary-material"}), which proved a strong impact of CTLA-4-mediated effects.^[@bib13]^ Interestingly, CTLA-4-triggered CTLs showed a pronounced re-expression of CD62L on day 2 ([Supplementary Figure S1d](#sup1){ref-type="supplementary-material"}).

After 48 h of stimulation, which marked the time-point of maximal CTLA-4 expression ([Supplementary Figure S2a](#sup1){ref-type="supplementary-material"}), the phosphorylated proteins were isolated, digested and the resulting phosphopeptides were measured for their abundance in two independent biological replicates. These analyses led to the detection of 89 phosphopeptides belonging to 74 proteins that were differentially regulated upon CTLA-4 engagement. Sixty-three of 89 peptides showed enhanced phosphorylated residues while 26 peptides were less phosphorylated. Among these proteins, PKC-η and VAV-1 have already been connected to CTLA-4.^[@bib14],\ [@bib15]^ As targets with multiple affected phosphopeptides, NUCKS and PDCD4 were found to be the most upregulated ones, whereas Fra-2 was the strongest dephosphorylated protein ([Figure 1a](#fig1){ref-type="fig"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The analysis of phosphorylation motifs in the CTLA-4-regulated phosphopeptides revealed specific but also common patterns like RxxS of overrepresented amino acid residues in down- and upregulated sites ([Figure 1b](#fig1){ref-type="fig"}). The RxxS motif could be recognized by PKA or CaMKII.^[@bib16]^

Furthermore, by using BABELOMICS functional annotation analysis software^[@bib17]^ we could allocate these proteins to six major GO:BP categories namely cytokine production, T-cell activation, RNA processing, mRNA metabolism, DNA replication and regulation of microtubule-based processes ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). These specifically enriched clusters further suggest a role for CTLA-4 in modulating central processes of CD8^+^ T-cell differentiation. With the NetworkAnalyst software^[@bib18]^ we created a interaction-network of 67 detected or predicted proteins with 81 connections. Proteins involved in the processes of T-cell activation and cytokine production are more closely connected than the proteins of the other functional clusters, rendering the former as primary CTLA-4 targets. Furthermore, this analysis revealed the central transcription factor FoxP3 as a central interaction hub for CTLA-4-regulated proteins ([Figure 1c](#fig1){ref-type="fig"}).^[@bib19]^

To analyze the extend of CTLA-4-mediated posttranslational modifications we further characterized the hypophosphorylation of the AP-1 family transcription factor Fra-2, which functions as a key regulator of T-cell differentiation.^[@bib20]^ As Fra-2 forms several bands in mobility gel shift assays upon phosphorylation we analyzed nuclear extracts of CD8^+^ T cells by immunoblotting.^[@bib21]^ On day 1, Fra-2 showed an equal phosphorylation pattern of three mobility gel shift bands in both CTLA-4-triggered and control cells, which was maintained in the latter over the following 2 days. CTLA-4 engagement however consistently led to a more than sevenfold reduction of Fra-2 phosphorylation forms in CD8^+^ T cells on day 2 and 3 ([Figure 2a](#fig2){ref-type="fig"}). To confirm that Fra-2 regulation is attributed to posttranslational effects, Fra-2 (*Fosl2*) mRNA was quantified and showed similar amounts in all stimulated samples ([Figure 2b](#fig2){ref-type="fig"}). Among the kinases that are able to phosphorylate Fra-2 we tested the involvement of PKA. The application of the specific PKA inhibitor 14-22 amide led to a more than 30% decreased formation of the slow (upper) and fast (lower) migrating Fra-2 phosphorylation forms in control cells, whereas increased PKA activity due to incubation with the cAMP elevator Forskolin specifically intensified those phosphorylation forms more than six times in CTLA-4-triggered cells ([Figure 2c](#fig2){ref-type="fig"}).

Collectively, these findings substantiate the significance of the mass spectrometry dataset for the identification of CTLA-4-mediated signaling effects and further revealed that hyperphosphorylation of Fra-2 integrates PKA signaling in differentiating CD8^+^ T cells.

CTLA-4 interferes with translation initiation via PDCD4 induction
-----------------------------------------------------------------

The iTRAQ mass spectrometry data revealed that CTLA-4 mediated a strong phosphorylation of the translational inhibitor PDCD4 at S94 and S457 ([Figure 1a](#fig1){ref-type="fig"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}), which could function as a capable post-transcriptional regulator.^[@bib22]^ First, we complemented our proteome results and analyzed PDCD4 S457 phosphorylation as well as total abundance by immunoblotting. Consistent with temporal CTLA-4 expression, we detected on day 2 and 3 a four- to fivefold increase of PDCD4 levels in CTLA-4-triggered CD8^+^ T cells. The protein was continuously phosphorylated and exclusively distributed in the cytoplasm of CD8^+^ T cells, where it can interfere with translation initiation ([Figure 3a](#fig3){ref-type="fig"}). To fulfill this function, PDCD4 has been shown to interact with the RNA helicase eIF4A to prevent the association of eIF4G.^[@bib23]^ To proof this relationship in CD8^+^ T cells, we conducted eIF4A IPs and quantified the amounts of co-immunoprecipitated eIF4G by immunoblotting.^[@bib24]^ Thereby, we detected threefold lower eIF4G protein amounts in eIF4A precipitates from CD8^+^ T cells differentiated with additional CTLA-4 engagement when compared with precipitates from control cells ([Figure 3b](#fig3){ref-type="fig"}).

In conclusion, we revealed a CTLA-4-mediated induction of the translational inhibitor PDCD4 that is localized in the cytoplasm where it interferes with protein translation initiation during CD8^+^ T-cell differentiation.

PDCD4 attenuates IFN-*γ* and anti-tumor responses of CTLs
---------------------------------------------------------

PDCD4 has originally been connected to apoptosis.^[@bib25]^ However, in this regard the analysis of PI and Annexin V staining showed no difference between WT and PDCD4-deficient CD8^+^ T cells ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Furthermore, PDCD4 has been shown to regulate the cytokine production of activated splenocytes and to be involved in autoimmune inflammation.^[@bib26]^ To exclusively determine the function of PDCD4 in physiologically activated CTLs, we cultured TCR transgenic CD8^+^ T cells from OT-I mice together with Ovalbumin-pulsed APCs ([Supplementary Figure S1a](#sup1){ref-type="supplementary-material"} lower) and controlled PDCD4 expression by immunoblotting as well as IFN-*γ* production by flow cytometry. Within the first 3 days, there was no detectable up-regulation of PDCD4 in CD8^+^ T cells that lack CTLA-4 expression, whereas CTLA-4 sufficiency led to threefold increased PDCD4 amounts at 72 h after T-cell activation ([Figure 3c](#fig3){ref-type="fig"}). Moreover, TCR transgenic PDCD4-deficient CD8^+^ T cells consistently showed 3-fold higher IFN-*γ* levels on day 3 in comparison to WT cells ([Figure 3d](#fig3){ref-type="fig"}). Notably, the absence of PDCD4 neither impaired CTLA-4 expression nor led to changes in the proliferative capacity of the cells ([Supplementary Figures S2b and c](#sup1){ref-type="supplementary-material"}).

CTLA-4 has been proven to restrict immune responses against malignant cells.^[@bib7],\ [@bib8]^ To initially assess a functional relevance of CTLA-4-induced PDCD4 expression for anti-tumoral CTL responses we compared the ability of TCR transgenic PDCD4- or CTLA-4-deficient CTLs to control the growth of Ovalbumin expressing B16 melanoma cells in an adoptive transfer model. On day 8 after T cell transfer, the mean tumor volume was more than fivefold smaller in mice that received PDCD4^−/−^ CD8^+^ T cells when compared with control mice ([Figures 4a and b](#fig4){ref-type="fig"}). We next analyzed the activated transferred peripheral CD8^+^ T cells regarding their relative abundance and capacity to produce IFN-*γ*. Consistently, PDCD4 deficiency led to significantly increased IFN-*γ* levels in the *in vivo* activated PDCD4^−/−^ CD8^+^ T cells whereas the numbers of antigen-specific CD8^+^ T cells did not significantly differ ([Figure 4c](#fig4){ref-type="fig"}).

Similar to the systemic effect of CTLA-4-blocking antibodies, we finally tested mice that completely lacked PDCD4 expression for their capacity to control tumor implantation. We therefore inoculated luciferase-expressing tumor cells in a prostate cancer model that had been shown to be susceptible for immune-checkpoint therapy.^[@bib9]^ The PDCD4-deficient as well as CTLA-4-blocked WT mice showed enhanced regression of implanted tumors when compared with untreated PDCD4-sufficient mice. Moreover, all PDCD4^−/−^ mice showed complete tumor rejection within two weeks, whereas only three of nine WT mice were tumor-free until day 14 ([Figures 4d and e](#fig4){ref-type="fig"}).

Taken together, these data demonstrated an important role for the translational inhibitor PDCD4 in the downregulation of the IFN-*γ* production in CTLs and implicated this mechanism of restricted protein expression to be critical for anti-tumor responses.

CTLA-4-mediated nuclear relocalization of FoxO1 promotes the expression of PDCD4
--------------------------------------------------------------------------------

To clarify a possible regulation of PDCD4 due to ubiquitin ligase mediated protein degradation,^[@bib24],\ [@bib27]^ we applied a proteasomal inhibitor during stimulation of CD8^+^ T cells. Despite a strong accumulation of ubiquitinated proteins, the immunoblot analysis showed no alteration in the relative PDCD4 abundance and therefore no involvement of this mechanism in the CTLA-4-mediated regulation of PDCD4 ([Figure 5a](#fig5){ref-type="fig"}). We further ruled out an implication of the PDCD4-targeting miR-21,^[@bib28]^ as evenly distributed micro-RNA levels could be detected ([Figure 5b](#fig5){ref-type="fig"}). The quantification of *Pdcd4* transcripts revealed a consistent abundance of mRNA levels in comparison with the respective protein amounts, suggesting a regulation of PDCD4 through mRNA expression ([Figures 5c](#fig5){ref-type="fig"} and [3a](#fig3){ref-type="fig"}). PDCD4 has been shown to be induced by the Foxo transcription factor.^[@bib29]^ In murine regulatory T cells, FoxO1 has been confirmed to bind within the 5′-UTR of the *Pdcd4* gene and loss of FoxO1 leads to decreased *Pdcd4* mRNA levels.^[@bib30]^ To assess the impact of FoxO1 on PDCD4 expression in CD8^+^ T cells, we applied an inhibitor of FoxO1 transactivation 24 h after beginning of T cell activation, which completely prevented the induction of PDCD4 ([Figure 5d](#fig5){ref-type="fig"}). Furthermore, we performed a *Foxo1* deletion through transduction of Foxo1^fl/fl^ CD8^+^ T cells with TAT-Cre recombinase.^[@bib31]^ This treatment led to both reduced FoxO1 and decreased PDCD4 protein levels with a concomitantly elevated production of IFN-*γ* ([Figure 5e](#fig5){ref-type="fig"}). Thus, PDCD4 upregulation is primarily dependent on FoxO1.

Upon T-cell activation, FoxO1 is regulated by a highly conserved mechanism that involves phosphorylation by Akt, leading to its cytoplasmic retention and subsequent inactivation.^[@bib32],\ [@bib33]^ Hence, we analyzed the cellular distribution of FoxO1 as well as phosphorylation events by immunoblotting to confirm CTLA-4-mediated FoxO1 activity. After 6 h of stimulation we consistently detected a strong Akt activation in all cells as determined by T308 and S473 phosphorylation. At the same time, FoxO1 was equally phosphorylated at the Akt site S253 and consequently localized in the cytoplasm. However, at 48 h FoxO1 was strongly enriched in the nuclei of CD8^+^ T cells that were differentiated with additional CTLA-4 engagement despite an equal reduction of Akt and FoxO1 phosphorylation in both CTLA-4-triggered and control cells ([Figure 5f](#fig5){ref-type="fig"}).

We therefore conclude that CTLA-4-mediated mechanisms led to an Akt-independent nuclear relocalization of the transcription factor FoxO1, resulting in augmented gene expression of the translational inhibitor PDCD4.

Targets of PDCD4 are critical for CTL responses
-----------------------------------------------

PDCD4 directly associates with mRNAs to repress the translation of the corresponding proteins.^[@bib34]^ To identify PDCD4 targets in CTLs we immunoprecipitated PDCD4 and subsequently sequenced the co-precipitated RNA fraction. The sequencing data revealed mRNA molecules derived from 21 different genes to be significantly enriched in the PDCD4 precipitates ([Figure 6a](#fig6){ref-type="fig"} and [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Among these targets, Glutaminase (*Gls*) and SENP3 have been shown to be essential for cellular metabolism and biosynthesis, thus playing a critical role in CTL responses.^[@bib35],\ [@bib36]^ We finally sought to compare the *in situ* mRNA levels of *Gls* and *Senp3* with the respective protein amounts to prove a direct effect of PDCD4 on the translation of these targets. Despite similar mRNA amounts, the Glutaminase and SENP3 protein levels were more than 50% lower in WT CD8^+^ T cells than in their PDCD4-deficient counterparts ([Figure 6b](#fig6){ref-type="fig"} and [Supplementary Figure S2d](#sup1){ref-type="supplementary-material"}). To further asses the influence of PDCD4-mediated effects on cellular glutaminolysis of CTLs we supplemented activated CD8^+^ T cells with glutamate. This treatment resulted in a significant increase in the IFN-*γ* production of WT cells ([Figure 6c](#fig6){ref-type="fig"}).

Together, these data show how CTLA-4-induced expression of PDCD4 might attenuate CD8^+^ T cell effector functions, leading to abrogated anti-tumor responses.

Discussion
==========

In this study we conducted a comprehensive analysis of CTLA-4-mediated intracellular changes in differentiating CTLs, which are a central part of the effector response towards antigenic tumors. The differentiation of naïve CD8^+^ T cells is characterized by an early commitment to an autonomous developmental program.^[@bib37]^ After 48 h, CTLA-4 is strongly expressed on the surface of CD8^+^ T cells, that continue to differentiate in absence of further activation and which already peak in gene transcription.^[@bib12],\ [@bib38]^ Consequently, CTLA-4 needs to act in a modulatory manner to attenuate CTLs responses rather than to solely ablate their stimulation.^[@bib39]^ In this study, we identified 89 CTLA-4-responding phosphorylation sites at 74 different proteins supporting the notion of CTLA-4-mediated posttranscriptional or -translational modifications of already established signaling circuits. Importantly, the applied differentiation system^[@bib4]^ enabled similar initial stimulation of all CD8^+^ T cells as verified by uniform values for every analyzed parameter 24 h after beginning of the stimulation. On day two, an inverse relation between IFN-*γ* and CTLA-4 was detectable, which has been previously reported for CD8^+^ T cells.^[@bib11],\ [@bib13]^

The mass spectrometric analysis provided unprecedented details on the signal network downstream of CTLA-4 and focusing on phosphorylated components significantly facilitated the detection of novel mechanisms. However, a further analysis of the phospho-proteins is required to characterize the identified regulation as a direct phosphorylation event. Interestingly, the protein interaction approach contributed several CTLA-4-regulated proteins capable to associate with the regulatory T-cell factor FoxP3.^[@bib19]^ Furthermore, the discovered CTLA-4-dependent phosphorylation of PKC-η at S675 adds valuable information to the previously for Treg cells described interaction.^[@bib14]^ Therefore, the findings in this study might also give indications for CTLA-4-mediated functions in other lymphocyte subpopulations.

The identification of common phosphorylation motifs implies the involvement of multiple kinases. In this regard, we characterized the phosphorylation of the AP-1 family transcription factor Fra-2 (*Fosl2*) which has been implicated in T-helper cell differentiation.^[@bib20]^ Consistently, we demonstrated in activated CD8^+^ T cells an initial strong phosphorylation leading to the formation of several gel mobility band shifts and that CTLA-4 engagement completely abrogated these pos-translational modifications.^[@bib21]^ This could be due to a regulation of the activity or the nuclear shuttling of the responsible kinases. Notably, *Fosl2* gene expression has recently been identified to be regulated in exhausted CD8^+^ T cells.^[@bib40]^

One of the most powerful CTLA-4-controlled proteins was the translational inhibitor PDCD4 that functions as a crucial posttranscriptional regulator.^[@bib22]^ The central impact of the CTLA-4-PDCD4 axis could be unambiguously demonstrated in several independent *in vitro* and *in vivo* settings, delineating the cell- and context-specific role of PDCD4 in attenuating effector responses of CTLs. This appears to be unlike to B lymphocytes, were PDCD4 is primarily involved in maintaining cell quiescence.^[@bib26]^ As the blockade of CTLA-4 is applied in tumor therapy, we initially assessed the role of its newly identified downstream target PDCD4 in the impairment of anti-tumor CTL responses. Our data demonstrate that a general and a CD8^+^ T-cell-specific deficiency of PDCD4 led to improved control of tumor growth. We consistently observed increased IFN-*γ* levels in PDCD4-deficient CTLs that could be responsible for an enhanced anti-tumor activity.^[@bib41]^ Although CD8^+^ T cells are the main effectors of the adaptive immune system that lyse malignant cells, a concomitant suppression through CTLA-4-expressing regulatory T cells further accounts for ineffective immune responses against tumors.^[@bib42]^ It is tempting to speculate that PDCD4 as a FoxP3 interacting and FoxO1-induced protein has likely a critical role in regulatory T cells as well, strengthening PDCD4 as a promising target for therapeutic interventions.^[@bib19],\ [@bib30]^

Furthermore, the identified main target of PDCD4 in CTLs, the rate-limiting enzyme Glutaminase, serves as a metabolic checkpoint during cell differentiation and has an important role in the anti-tumor response, as its substrate glutamine provides an essential source for the cellular metabolism of CTLs in the glucose-deprived tumor microenvironment.^[@bib35],\ [@bib43]^ In line with the function as a translational inhibitor, we revealed that PDCD4 expression caused a downregulation of the SUMO-specific protease SENP3, which has been shown to act as a crucial factor in ribosome biogenesis.^[@bib36]^ In conclusion, CTLA-4-mediated PDCD4 expression induced a defined restriction of protein translation that critically shaped the quality of CTLs leading to impaired anti-tumor responses.

The global blockade of CTLA-4 impinges on more than one pathway, which is also reflected by the detected positive feedback of CTLA-4 on FoxO1. This transcription factor not only regulated PDCD4 expression but furthermore controls several proteins critical for CD8^+^ T-cell differentiation-like CD62L or TCF-1.^[@bib44],\ [@bib45],\ [@bib46]^ Thus, dissecting CTLA-4-initiated pathways might identify targets which primarily control single aspects of anti-tumor immune responses.

Interestingly, the CTLA-4-mediated FoxO1 regulation occurred independently of Akt, indicating a central cellular role of FoxO1 downstream of multiple pathways. In this regard, FoxO1 has recently been shown to be activated by PD-1 and to promote CD8^+^ T-cell exhaustion.^[@bib47]^ Moreover, increased PDCD4 mRNA levels have been detected in chronically activated CD8^+^ T cells.^[@bib48]^ Thus, the induction of PDCD4 expression by FoxO1 could be a part of a redundant mechanism that is addressed by both CTLA-4 and PD-1. In T-helper cells, PDCD4 has already been confirmed as a target of PD-1 (ref. [@bib49]). As a consequence, PDCD4 could be upregulated even in CTLs that do not express CTLA-4 at a given time and the same relation could account for PD-1. This notion would further support the observed superior anti-tumor response of PDCD4-deficient CD8^+^ T cells being similar to synergistic effects of a combinatory CTLA-4 and PD-1 blockade.^[@bib50]^

Taken together, the control of protein biosynthesis through the induction of the translational inhibitor PDCD4 marks an important immune-checkpoint in CTL differentiation. Our data further suggests novel targets on CTLs that evoke posttranscriptional strategies for improving anti-tumor immune-checkpoint therapy.

Materials and Methods
=====================

Mice
----

OVA-specific TCR^tg^ mice (OT-I) both CTLA-4^+/+^ and PDCD4^+/+^ or CTLA-4^−/−^ or PDCD4^−/−^, as well as Ly5.1, C57BL/6 and PDCD4^−/−^ mice were bred under specific pathogen-free conditions in the central animal facility of the University of Magdeburg Medical School (Germany). OT-I TCR^tg^ was controlled by flow cytometry and both CTLA-4^−/−^ and PDCD4^−/−^ mice were genotyped as described elsewhere.^[@bib13],\ [@bib26]^ All animal experiments were performed in accordance with institutional, state and federal guidelines.

Antibodies
----------

The following antibodies against murine antigens were used: *α* CD152 (UC10-4F10), isotype control antibody (A19-3), *α* Vα2-TCR (B20.1), *α* T-bet (O4-46), *α* CD44 (IM7), *α* CD45.2 (104) (BD Biosciences, Franklin Lakes, NJ, USA); *α* CD3 (145-2C11), *α* CD28 (37.51), *α* CD8a (53-6.7), *α* CD62L (MEL-14), *α* IFN-*γ* (XMG1.2) (BioLegend, Koblenz, Germany); *α* Fra-2 (Q20), *α* GAPDH (A3), *α* eIF4A (yN-20) (Santa Cruz Biotechnology, Dallas, TX, USA); *α* PDCD4 (D29C6), *α* eIF4G (C45A4), *α* eIF4A (C32B4), *α* FoxO1 (C29H4), *α* phospho-FoxO1^S253^, *α* phospho-AKT^S473^, *α* phospho-AKT^T308^, *α* Akt (pan) (C67E7), *α* SENP3 (D20A10), *α* Aldolase A (D73H4), *α* Lamin B1, *α* Ubiquitin (P4D1) (Cell Signaling Technology, Danvers, MA, USA); *α* phospho-PDCD4^S457^ (9G6) (Rockland Immunochemicals, Limerick, PA, USA); *α* Glutaminase (EP7212) (Abcam, Cambridge, UK). For *in vivo* antibody treatment of mice *α* CTLA-4 (UC10-4F10) were purified from hybridoma supernatants and controlled by flow cytometry. *α* DEC-OVA conjugates were produced as previously described.^[@bib51]^

Cell isolation and stimulation
------------------------------

Isolation of APCs or naïve CD8^+^ CD44^low^ CD62L^high^ T cells from spleens, inguinal- and axillary-lymph nodes was performed with *α* CD90 microbeads or α CD8a-FITC and *α* FITC microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Isolated CD8^+^ T cells from C57BL/6 mice were stimulated with antibodies immobilized on microspheres (Thermo Fisher Scientific, Waltham, MA, USA). Microspheres were coated as described elsewhere.^[@bib4]^ The following concentrations were used: 0.75 μg/ml *α* CD3, 2 μg/ml *α* CD28 and 7 μg/ml *α* CTLA-4 or isotype control antibody. Cells were cultured with complete medium (RPMI, with 100 U/ml Penicillin, 100 μg/ml Streptomycin (Thermo Fisher Scientific), and 10% FCS (Biochrom, Berlin, Germany)) supplemented with 10 ng/ml of recombinant IL-2 (Miltenyi Biotec) and 10 ng/ml of recombinant IL-12 (BioLegend). CD8^+^ T cells from TCR-transgenic OT-I mice were stimulated with 100 μg/ml OVA and 0.2 μg/ml *α* DEC-OVA in complete medium supplemented with 1 ng/ml IL-2 and 1 ng/ml IL-12 and CD90 depleted splenocytes from congenic C57BL/6 mice or with OVA~257-264~ peptide-pulsed microspheres loaded with 1 μg/ml DimerX I fusion protein (BD Biosciences), 5 μg/ml B7.1-Fc (BioLegend) and 8 μg/ml *α* CTLA-4. In some experiments, CD8^+^ T cells were treated with 4 mM [L]{.smallcaps}-glutamic acid (Sigma-Aldrich, Munich, Germany) for 60 h prior analysis.

TAT-Cre transduction
--------------------

Foxo1^fl/fl^ cells and TAT-Cre recombinase were kindly provided by K. Rajewsky (Max Delbrück Center for Molecular Medicine, Berlin, Germany). Purified Foxo1^fl/fl^ CD8^+^ T cells were washed in serum-free medium (HyClone Laboratories, Logan, UT, USA), prewarmed and transduced with sterile-filtrated TAT-Cre dilution^[@bib31]^ at a density of 5 × 10^6^ cells/ml for 45 min at 37 °C. Cells were then washed in complete medium and differentiated with 0.75 μg/ml *α* CD3, 2 μg/ml *α* CD28 and 7 μg/ml *α* CTLA-4 antibodies attached to microspheres in complete medium supplemented with 10 ng/ml of recombinant IL-2 and 10 ng/ml of recombinant IL-12. Mock-transduced CD8^+^ T cells were identically treated except of omitted recombinase.

Flow cytometry
--------------

For intracellular IFN-*γ* staining *α* CD3/*α* CD28/*α* CTLA-4 or APC-activated cells were treated with 5 μg/ml Brefeldin A for 3 h, DimerX I/B7.1-Fc/*α* CTLA-4 activated or *ex vivo* analyzed cells with 10 μg/ml PMA, 1 μg/ml Ionomycin and 5 μg/ml Brefeldin A for 4 h, fixed and permeabilized with 0.5% saponin (Sigma-Aldrich). In some experiments, cells were loaded with CFSE (Thermo Fisher Scientific) prior activation. Intracellular T-bet staining was performed using a FoxP3 buffer set (Thermo Fisher Scientific). Cytometric measurements were performed on a FACS-Canto II (BD Biosciences) and analyzed with FlowJo (Tree Star, Ashland, OR, USA) software.

iTRAQ mass spectrometric analysis of phosphorylated proteins
------------------------------------------------------------

Isolated phosphorylated proteins of CD8^+^ T cells from day 2 after differentiation with or without additional CTLA-4 engagement were comparatively analyzed by iTRAQ mass spectrometry. Fifteen minutes before analysis, cells were thoroughly re-suspended, shortly centrifuged and incubated at 37 °C to ensure active contacts. Detailed proteomic methods and phospho-peptide sequencing are described in [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}.

Immunoprecipitation and immunoblotting
--------------------------------------

Immunoprecipitation was performed with Protein G Microbeads (Miltenyi Biotec) according to the manufacturer's instructions. In brief, CD8^+^ T cells were lysed and incubated in NP-40 lysis buffer with *α* eIF4A (yN-20) and 10 mM NaCl or *α* PDCD4 or *α* Aldolase A antibodies with 100 mM NaCl and Protein G microbeads, and subsequently purified by positive selection. Immunoprecipitation of PDCD4 or Aldolase A was conducted with extracts of CD8^+^ T cells on day 2 after differentiation with *α* CD3, *α* CD28 and additional CTLA-4 engagement. APC-activated CD8^+^ T cells were isolated with *α* CD8a-FITC and *α* FITC microbeads before protein extraction. Cellular extracts or immunoprecipitates were separated on 10% SDS-PAGE gels and transferred onto nitrocellulose membranes. Blots were probed with antibodies, visualized and quantified using the Odyssey scanner and software (LI-COR, Lincoln, NE, USA). In some experiments the CD8^+^ T cells were treated with 100 μg/ml Cycloheximide (AppliChem, Darmstadt, Germany) or 40 μM Forskolin (Sigma-Aldrich) or 10 μM 14-22 amid for 60 min or 5 μM MG132 for 2 h or 0.5 μM AS1842856 (Merck Millipore, Darmstadt, Germany) for 24 h before protein extraction.

Next-generation sequencing and qPCR measurement of mRNA or microRNA
-------------------------------------------------------------------

Small and large RNAs from CD8^+^ T cells or immunoprecipitates were extracted by using NucleoSpin miRNA Kit and RNA Kit (Macherey-Nagel, Düren, Germany), respectively. Detailed methods for preparation of cDNA libraries, as well as sequencing and detection of RNA levels see [Supplementary Materials and Methods](#sup1){ref-type="supplementary-material"}.

Animal procedures
-----------------

Ly5.1 recipient mice were s.c. inoculated with 2 × 10^5^ B16-OVA cells. B16-OVA cells were kindly provided by J. Huehn (Helmholtz Centre for Infection Research, Braunschweig, Germany).^[@bib52]^ Congenic naive CD8^+^ OT-I T cells (3.3 × 10^6^) both CTLA-4^+/+^ and PDCD4^+/+^ or CTLA-4^−/−^ or PDCD4^−/−^ were i.v. injected 5 days later. Tumor size was monitored by measurement in three dimensions with a caliper and calculated as hemi-elliptical volume. Blood samples were taken on day 6 after CD8^+^ T-cell transfer. In the tumor model with prostate cancer cells,^[@bib9]^ 2 × 10^6^ Luciferase-expressing TRAMP-C1 cells (Applied Biological Materials, Richmond, BC, Canada) were s.c. inoculated into PDCD4 WT or deficient mice. Part of the WT mice additionally received 100 μg i.p. injections of *α* CTLA-4 antibody on day 6, 10 and 13. Complete eradication of TRAMP-C1 Luc tumors was controlled by *in vivo* luminescence imaging. In brief, luciferin (150 mg/kg) was injected i.v. and mice were anesthetized with isoflurane and measured by IVIS 200 *in vivo* imaging system (PerkinElmer, Waltham, MA, USA).

Statistical analysis
--------------------

*P*-values\<0.05 were considered statistical significant and calculated with a two-sided Mann--Whitney rank sum test for the comparison of two groups; for more than two groups a Kruskal--Wallis test with Dunn's correction was used. All determined significances remained by using an equivalent parametric test. The percentage of tumor-bearing mice was calculated with a Log rank (Mantel--Cox) test. The determination of significantly different phosphopeptides was performed by the discrimination of regulated from randomly fluctuating values in a large number of small samples.^[@bib53]^ Statistical significance is indicated as followed: ns, not significant, \**P*\<0.05 and \*\*\**P*\<0.001.
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![CTLA-4 modulates the phosphoproteome in differentiating CD8^+^ T cells. (**a**) Comparative phosphorylation profile of significantly (*P*\<0.05) regulated proteins in CD8^+^ T cells from day 2 after differentiation with *α* CD3, *α* CD28 and additional CTLA-4 engagement or not, acquired by iTRAQ mass spectrometry in two independent experiments (E1, E2). Proteins were aligned according to GO:BP semantic relations.^[@bib54]^ Blue and red represent low and high relative phosphorylation, respectively. Refer to [Supplementary Table S1](#sup1){ref-type="supplementary-material"} for complete data. (**b**) Significantly (*P*\<0.001) overrepresented amino acid residues in motifs containing dephosphorylated (left panel; blue) or stronger phosphorylated (right panel; red) serine residues in CD8^+^ T cells upon CTLA-4 engagement. Sequences (±7 residues) of the identified sites in (**a**) were analyzed with the PhosphoSitePlus motif analysis generator using the exhaustive 1--2 AA algorithm.^[@bib55]^ (**c**) Possible interactions of the CTLA-4-affected proteins from **a** analyzed by the NetworkAnalyst software.^[@bib18]^ A GO:BP enrichment analysis was performed to highlight functional subsets significantly (*P*\<0.001) affected by CTLA-4 engagement. See also [Supplementary Table S2](#sup1){ref-type="supplementary-material"}](cdd2017102f1){#fig1}

![CTLA-4 mediates Fra-2 dephosphorylation during CD8^+^ T-cell differentiation. (**a**) Immunoblot analysis of total and phosphorylated Fra-2 in nuclear extracts of CD8^+^ T cells from day 1, 2, and 3 after differentiation with *α* CD3, *α* CD28, and additional CTLA-4 engagement or not. (**b**) *Fosl2* (Fra-2) mRNA expression profile of CD8^+^ T cells after differentiation as described in (**a**). (**c**) Immunoblot analysis of phosphorylated Fra-2 (p-Fra-2) in nuclear extracts from day 2 of CD8^+^ T cells after differentiation as described in (**a**), treated for 60 min with vehicle, 14--22 amid or Forskolin. Numbers represent relative protein amounts of the phosphorylated gel mobility shifts normalized as indicated. Data are representative of *n*=2--3 independent experiments. Data points represent individual mice with mean+S.D. ns, not significant, calculated by Mann--Whitney test](cdd2017102f2){#fig2}

![CTLA-4 induces PDCD4 to restrict protein translation and IFN-*γ* production. (**a**) Immunoblot analysis of PDCD4 (total and S457-phosphorylated) in subcellular extracts of CD8^+^ T cells from day 1, 2 and 3 after differentiation with *α* CD3, *α* CD28 and additional CTLA-4 engagement or not. (**b**) Immunoblot analysis of eIF4A immunoprecipitates (IP) or whole cell lysates (WCL) of CD8^+^ T cells from day 2 after differentiation as described in **a** treated with Cycloheximide prior protein extraction. The co-immunoprecipitated eIF4G was quantified to eIf4A (right panel). (**c**) Immunoblot for PDCD4 (total and S457-phosphorylated) in whole-cell lysates of TCR-transgenic CTLA-4 WT or deficient OT-I CD8^+^ T cells from day 2 and 3 after differentiation with APCs and OVA. (**d**) IFN-*γ* production of TCR-transgenic CTLA-4 and PDCD4 WT or CTLA-4- or PDCD4-deficient OT-I CTLs differentiated as described in (**c**). IFN-*γ*-positive cells were determined by flow cytometry and normalized to WT. Numbers represent relative protein amounts normalized as indicated. Data are representative of *n*=2--4 independent experiments. Data points represent individual mice with mean+S.D. \**P*\<0.05; ns, not significant, calculated by Mann--Whitney test for (**b**) or by Kruskal--Wallis test with Dunn's correction for (**d**)](cdd2017102f3){#fig3}

![PDCD4 deficiency leads to enhanced control of experimental tumors. (**a**) Tumor growth curves of mice s.c. inoculated with B16-OVA melanoma cells, followed 5 days later by i.v. transfer of no T cells (gray) or OT-I TCR-transgenic CTLA-4 and PDCD4 WT (black) or CTLA-4- (red) or PDCD4-deficient (blue) CD8^+^ T cells. Thin lines represent individual tumors and bold lines the mean tumor growth (*n*=4--8). (**b**) Tumor volume of (**a**) on day 8 after transfer. (**c**) Frequencies of total CD8^+^ T cells (left) and IFN-*γ* producers (right) of i.v. injected peripheral CD62L^lo^ CD8^+^ T cells on day 6 after transfer as described in (**a**) determined by flow cytometry. (**d**) Bioluminescence images of PDCD4 WT and deficient mice from day 5 or day 9 after s.c. inoculation of TRAMP-C1 Luc prostate cancer cells. (**e**) Frequency of tumor bearing WT (solid black line, *n*=9), WT CTLA-4-blocked (dashed line, *n*=3) or PDCD4-deficient (solid blue line, *n*=6) mice as described in (**d**). Data points represent individual mice with mean+S.D. \**P*\<0.05, \*\*\**P*\<0.001; ns - not significant, calculated by Kruskal--Wallis test with Dunn's correction for (**b** and **c**) or by Log rank (Mantel--Cox) test for (**d**)](cdd2017102f4){#fig4}

![CTLA-4 mediates PDCD4 expression via FoxO1 reactivation. (**a**) Immunoblot analysis of PDCD4 and ubiquitinated proteins in CD8^+^ T cells from day 2 after differentiation with *α* CD3, *α* CD28 and additional CTLA-4 engagement or not, treated for 2 h with vehicle or MG132 prior cell lysis. (**b**) *miR-21* or (**c**) *Pdcd4* mRNA expression profile of CD8^+^ T cells after differentiation as described in **a**. (**d**) Immunoblot analysis of PDCD4 in CD8^+^ T cells from day 1 and 2 after differentiation as described in **a**, treated on day 1 for 24 h with vehicle or AS1842856. (**e**) Immunoblot analysis of whole-cell lysates of Foxo1^fl/fl^ CD8^+^ T cells from 60 h after treatment with TAT-Cre recombinase or not (Mock) followed by differentiation with *α* CD3, *α* CD28 and additional CTLA-4 engagement. Cells were further analyzed by flow cytometry for IFN-*γ* production (lower panel). (**f**) Immunoblot analysis of FoxO1 (total and S253-phosphorylated) and Akt (pan and T308- or S473-phosphorylated) in subcellular extracts of CD8^+^ T cells from 6 and 48 h after differentiation as described in (**a**). Data are representative of *n*=2--4 independent experiments. Numbers represent relative protein amounts normalized as indicated. Data points represent individual mice with mean+S.D. \**P*\<0.05; ns, not significant, calculated by Mann--Whitney test](cdd2017102f5){#fig5}

![PDCD4-targeted protein translation. (**a**) Significantly enriched mRNAs in PDCD4 immunoprecipitates of CD8^+^ T cells from day 2 after differentiation with *α* CD3, *α* CD28 and additional CTLA-4 engagement. Data were aligned according to GO:BP semantic relations.^[@bib54]^ See also [Supplementary Table S3](#sup1){ref-type="supplementary-material"}. (**b**) Immunoblot analysis of Glutaminase, SENP3 and PDCD4 in subcellular extracts of OT-I TCR-transgenic PDCD4 WT or deficient CD8^+^ T cells from day 5 after differentiation with OVA-peptide pulsed microspheres loaded with DimerX I, B7.1-Fc and *α* CTLA-4. Numbers represent relative protein amounts normalized as indicated. (**c**) Flow cytometric analysis (left) and cumulative graph (right) of glutamate-induced IFN-*γ* in OT-I TCR-transgenic PDCD4 WT or deficient CD8^+^ T cells from day 5 after differentiation as described in (**b**), supplemented with glutamate 60 h prior measurement. Data are representative of *n*=2--4 independent experiments. Data points represent individual mice with mean+S.D. \**P*\<0.05, calculated by Mann--Whitney test](cdd2017102f6){#fig6}
